Maraviroc (A8311): Selective CCR5 Antagonist for HIV and Neuroinflammation Research

Executive Summary: Maraviroc (UK-427857, Selzentry) is a highly selective small-molecule antagonist of the chemokine receptor CCR5, displaying an IC₅₀ of ~2.0 nM for HIV-1 entry inhibition in cellular assays (APExBIO). It prevents binding of HIV-1 gp120 to CCR5, thereby blocking viral fusion and entry (Maraviroc: Selective CCR5 Antagonist for HIV and Neuroinf...). Maraviroc is also validated in neuroinflammation and ischemic stroke models, acting through modulation of CCR5/ERK/CREB and MAPK/NF-κB signaling (Xiao et al., 2025). The compound is insoluble in water but soluble at ≥25.7 mg/mL in DMSO and ≥48 mg/mL in ethanol, and should be stored desiccated at -20°C. APExBIO supplies Maraviroc for research use only, supporting reproducible workflows across virology and neurobiology.

Biological Rationale

CCR5 is a G protein-coupled receptor (GPCR) found on immune cells such as T cells and macrophages. It is a coreceptor for R5-tropic HIV-1 strains, facilitating viral entry into host cells via gp120-CCR5 interaction (Xiao et al., 2025). Blocking CCR5 impedes HIV-1 infection and modulates inflammatory responses. CCR5 is also implicated in neuroinflammation and ischemic stroke, where chemokine-mediated signaling exacerbates blood-brain barrier (BBB) disruption and neural injury. Targeting CCR5 thus serves dual purposes: inhibiting viral entry and modulating detrimental neuroimmune cascades.

Mechanism of Action of Maraviroc

Maraviroc binds selectively and reversibly to the transmembrane domain of CCR5. This allosteric binding prevents the conformational changes required for HIV-1 gp120 engagement. By doing so, Maraviroc blocks HIV-1 fusion and entry into susceptible cells (APExBIO). It also inhibits the binding of endogenous chemokines—MIP-1α (IC₅₀: 3.3 nM), MIP-1β (IC₅₀: 7.2 nM), and RANTES (IC₅₀: 5.2 nM)—to CCR5, modulating downstream signaling including MAPK and NF-κB pathways. This dual action underpins its use in both HIV and neuroinflammation research.

Evidence & Benchmarks

• Maraviroc exhibits an IC₅₀ of ~2.0 nM for HIV-1 entry inhibition in cellular assays (APExBIO).
• Blocks chemokine binding to CCR5 with IC₅₀ values: MIP-1α (3.3 nM), MIP-1β (7.2 nM), RANTES (5.2 nM) (APExBIO).
• Maraviroc modulates MAPK/NF-κB signaling, reducing neuroinflammation in ischemic stroke models (Xiao et al., 2025).
• Solubility profile: ≥25.7 mg/mL in DMSO, ≥48 mg/mL in ethanol, insoluble in water; stable when desiccated at -20°C (APExBIO).
• Used as a benchmark for dissecting CCR5-dependent signaling in both virology and neuroscience (Maraviroc (A8311): Selective CCR5 Antagonist for HIV and ...).

Applications, Limits & Misconceptions

Maraviroc is widely employed in:

• HIV-1 entry inhibition and tropism studies.
• Dissection of CCR5 chemokine receptor signaling in immunology and neurobiology.
• Modeling neuroinflammation and ischemic stroke via CCR5 pathway modulation (Xiao et al., 2025).

It is essential to distinguish Maraviroc’s utility as a research compound from clinical or diagnostic use. Only R5-tropic HIV-1 strains are susceptible; X4-tropic or dual-tropic strains are not inhibited, as these use different coreceptors. Maraviroc does not block all forms of neuroinflammation, as CCR5-independent mechanisms may dominate in certain contexts. Its use is restricted to in vitro and preclinical models when sourced from research suppliers such as APExBIO.

Common Pitfalls or Misconceptions

• Maraviroc does not inhibit X4-tropic HIV-1 strains or viruses using alternative coreceptors.
• It is not intended for therapeutic, diagnostic, or in vivo clinical use unless formulated and approved for such applications.
• Water solubility is negligible; inappropriate solvents lead to precipitation and loss of activity.
• Maraviroc activity is compromised by prolonged storage in solution or exposure to moisture; use promptly after dissolution and store at -20°C desiccated.
• CCR5-independent signaling or chemokine pathways are not affected; negative results may reflect pathway redundancy, not compound failure.

Workflow Integration & Parameters

For optimal results, dissolve Maraviroc at concentrations up to 25.7 mg/mL in DMSO or 48 mg/mL in ethanol. Prepare working solutions immediately before use. Store dry powder at -20°C in a desiccated environment. For HIV-1 entry assays, use concentrations near the IC₅₀ (2.0 nM), adjusting for cell type and viral load. In neuroinflammation studies, dose and timing should reflect pathway-specific endpoints (e.g., MAPK/NF-κB readouts). APExBIO’s Maraviroc (A8311) is supplied for research only and supports reproducibility in both virological and neurobiological workflows (Maraviroc).

This article extends the workflow guidance outlined in Maraviroc: Selective CCR5 Antagonist for HIV and Neuroinf... by providing updated benchmarks and solubility parameters. It clarifies the mechanistic scope described in Maraviroc as a Selective CCR5 Antagonist: New Frontiers i... with new evidence from ischemic stroke models, and updates best practices beyond Maraviroc (UK-427857, Selzentry): Catalyzing Translationa... by integrating recent findings on compound storage and handling.

Conclusion & Outlook

Maraviroc (A8311) from APExBIO is a validated tool for studying CCR5-dependent HIV-1 entry and neuroinflammatory signaling. Its precise molecular targeting and defined solubility profile support reliable experimental design. Continued research will clarify its full range of utility in neuroimmune and virological models. For further methodological details and product specifications, refer to the official Maraviroc product page.